(Q38528130)

3 September 2017

1 reference

title

Treatment of ALK-Rearranged Non-Small Cell Lung Cancer: Recent Progress and Future Directions (English)

1 reference

3 September 2017

Laird Cameron

1

1 reference

3 September 2017

Benjamin Solomon

series ordinal

2

1 reference

3 September 2017

publication date

1 July 2015

1 reference

3 September 2017

1 reference

3 September 2017

volume

75

1 reference

3 September 2017

issue

10

1 reference

3 September 2017

page(s)

1059-1070

1 reference

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

3 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

First-line crizotinib versus chemotherapy in ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Targeting anaplastic lymphoma kinase in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

ALKoma: a cancer subtype with a shared target

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Comprehensive histologic analysis of ALK-rearranged lung carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1,683 patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Clinical Experience With Crizotinib in Patients With Advanced ALK-Rearranged Non-Small-Cell Lung Cancer and Brain Metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Testing for ALK rearrangement in lung adenocarcinoma: a multicenter comparison of immunohistochemistry and fluorescent in situ hybridization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

FDA approval summary: crizotinib for the treatment of metastatic non-small cell lung cancer with anaplastic lymphoma kinase rearrangements

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Crizotinib in ROS1-rearranged non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement: results from the EUROS1 cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Refining the toxicity profile of crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Treating ALK-positive lung cancer--early successes and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Patient-derived models of acquired resistance can identify effective drug combinations for cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Synthesis, structure-activity relationships, and in vivo efficacy of the novel potent and selective anaplastic lymphoma kinase (ALK) inhibitor 5-chloro-N2-(2-isopropoxy-5-methyl-4-(piperidin-4-yl)phenyl)-N4-(2-(isopropylsulfonyl)phenyl)pyrimidine-2,

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Ceritinib in ALK-rearranged non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Alectinib shows potent antitumor activity against RET-rearranged non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

In vivo imaging models of bone and brain metastases and pleural carcinomatosis with a novel human EML4-ALK lung cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Alectinib salvages CNS relapses in ALK-positive lung cancer patients previously treated with crizotinib and ceritinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Translational pharmacokinetic-pharmacodynamic modeling for an orally available novel inhibitor of anaplastic lymphoma kinase and c-Ros oncogene 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

Activity of IPI-504, a Novel Heat-Shock Protein 90 Inhibitor, in Patients With Molecularly Defined Non–Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-015-0415-9

FDA approval: ceritinib for the treatment of metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer.

21 January 2018

1 reference

PubMed

12 December 2020

1 reference

12 December 2020

A genomics-based classification of human lung tumors

1 reference

PubMed

12 December 2020

Crizotinib and testing for ALK.

1 reference

PubMed

12 December 2020

10.1007/S40265-015-0415-9

Identifiers

DOI

1 reference

Dimensions Publication ID

3 September 2017

1046329408

0 references

1 reference